Pharmtechnology, LLC
🇧🇾Belarus
- Country
- 🇧🇾Belarus
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://ft.by/en/okomp-2
Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions
Phase 1
- Conditions
- Bioequivalence
- Interventions
- Drug: Arcoxia® film-coated tablet 120 mg
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 34
- Registration Number
- NCT04830579
- Locations
- 🇷🇺
Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl", Yaroslavl, Russian Federation
Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions
Phase 1
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 34
- Registration Number
- NCT04753489
- Locations
- 🇷🇺
Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl", Yaroslavl, Russian Federation
Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions
Phase 1
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 34
- Registration Number
- NCT04729998
- Locations
- 🇷🇺
Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl", Yaroslavl, Russian Federation
A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions
Phase 1
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04138888
- Locations
- 🇨🇦
Altasciences Company Inc., Mont-Royal, Quebec, Canada
Single Dose Crossover Comparative Bioavailability Study of Two Formulations of Fluconazole 200 mg in Healthy Adult Subjects Under Fasting Conditions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 26
- Registration Number
- NCT04038008
- Locations
- 🇨🇦
Altasciences Company Inc., Mont-Royal, Quebec, Canada
The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 40
- Registration Number
- NCT04012307
- Locations
- 🇨🇦
Altasciences Company Inc., Mont-Royal, Quebec, Canada
The Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil After a Single Oral Dose Administration Under Fasting Conditions.
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03951051
- Locations
- 🇨🇦
Altasciences Company Inc., Mont-Royal, Quebec, Canada
Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03918551
- Locations
- 🇨🇦
Altasciences Company Inc., Montréal, Quebec, Canada
Bioequivalence Study of Two Formulations of Propafenone 300 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03915340
- Locations
- 🇨🇦
Altasciences Company Inc., Mount-Royal, Quebec, Canada
Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 34
- Registration Number
- NCT03898193
- Locations
- 🇷🇺
State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2", Yaroslavl, Yaroslavl Region, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath